Overview

Study to Compare How the Body Changes the Blood Level of Darifenacin Tablet Form vs. the Modified Release Liquid Form in Healthy Subjects

Status:
Completed

Trial end date:
2007-09-01

Target enrollment:

Participant gender:

Summary

This purpose of this study is to compare the how the body changes the blood level of a single dose of darifenacin when given as 7.5 mg modified release tablet and the modified release liquid suspension (1.5 mg/ml) under fasted and fed conditions in healthy subjects.

Phase:

Phase 1

Details

Lead Sponsor:

Novartis

Collaborator:

Procter and Gamble

Treatments:

Darifenacin